European Medicines Agency decision
P/0116/2012

of 2 July 2012

on the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (Yervoy),

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.
European Medicines Agency decision
P/0116/2012

of 2 July 2012

on the acceptance of a modification of an agreed paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP02-10-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency’s decision P/128/2011 issued on 8 June 2011 and the decision P/265/2011 issued on 28 October 2011,

Having regard to the application submitted by Bristol-Myers Squibb Pharma EEIG on 24 February 2012 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 May 2012, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

Has adopted this decision:

**Article 1**

Changes to the agreed paediatric investigation plan for ipilimumab (Yervoy), concentrate for solution for infusion, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

**Article 2**

This decision is addressed to Bristol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, UB8 1DH – Uxbridge, United Kingdom.

Done at London, 2 July 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)
Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan
EMEA-000117-PIP02-10-M02

Scope of the application

Active substance(s):
Ipilimumab

Invented name:
Yervoy

Condition(s):
Treatment of melanoma

Authorised indication(s):
See Annex II

Pharmaceutical form(s):
Concentrate for solution for infusion

Route(s) of administration:
Intravenous use

Name/corporate name of the PIP applicant:
Bristol-Myers Squibb Pharma EEIG

Information about the authorised medicinal product:
See Annex II
Basis for opinion


The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 19 March 2012.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 16 May 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan
1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of melanoma.

2.1.1. Indication(s) targeted by the PIP

Treatment of pre-treated and naive patients with advanced metastatic melanoma.

Treatment of patients with melanoma (surgically resected) in the adjuvant setting.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 12 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion.

2.1.4. Studies

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of studies</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Non-clinical</td>
<td>1</td>
<td><strong>Study 1</strong> Intravenous study of pre- and postnatal development in cynomolgus monkeys with a 6-month postnatal evaluation.</td>
</tr>
</tbody>
</table>
| Clinical   | 3                 | **Study 2** Open-label, dose escalation clinical trial of intravenously administered ipilimumab in children from 2 to less than 18 years (and in young adults to 21 years) with untreatable, refractory or relapsed solid malignant tumours.  
**Study 3** Open-label, multi-centre, single-arm clinical trial of intravenously administered ipilimumab in children aged 12 to less than 18 years with untreated or previously treated advanced/metastatic melanoma.  
**Study 4** Open-label randomized active-controlled study of adjuvant ipilimumab anti-CTLA4 therapy versus high-dose interferon α-2b in children aged 12 to less than 18 years (and adults) with resected high-risk melanoma. |
3. **Follow-up, completion and deferral of PIP**

<table>
<thead>
<tr>
<th>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</th>
<th>Yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of completion of the paediatric investigation plan:</td>
<td>By June 2018</td>
</tr>
<tr>
<td>Deferral for one or more studies contained in the paediatric investigation plan:</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Annex II

Information about the authorised medicinal product
Condition(s) and authorised indication(s):

1. Treatment of Melanoma

   Authorised indications: Yervoy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy.

<table>
<thead>
<tr>
<th>EU number</th>
<th>Invented name</th>
<th>Strength</th>
<th>Pharmaceutical Form</th>
<th>Route of Administration</th>
<th>Packaging</th>
<th>Content (concentration)</th>
<th>Package size</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/11/698/001</td>
<td>Yervoy</td>
<td>5 mg/ml</td>
<td>Concentrate for solution for infusion</td>
<td>Intravenous use</td>
<td>vial (glass)</td>
<td>10 ml</td>
<td>1 vial</td>
</tr>
<tr>
<td>EU/1/11/698/002</td>
<td>Yervoy</td>
<td>5 mg/ml</td>
<td>Concentrate for solution for infusion</td>
<td>Intravenous use</td>
<td>vial (glass)</td>
<td>40 ml</td>
<td>1 vial</td>
</tr>
</tbody>
</table>